royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Company profile
Ticker
RPRX
Exchange
Website
CEO
Pablo Gerardo Legorreta
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Royalty Pharma Holdings Ltd • RPI 2019 Intermediate Finance • RPI Acquisitions (Ireland) Limited • RPI Finance • RP IP HoldCo (Ireland) Limited ...
RPRX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Feb 24
8-K
Results of Operations and Financial Condition
15 Feb 24
8-K
Other Events
6 Feb 24
UPLOAD
Letter from SEC
30 Jan 24
CORRESP
Correspondence with SEC
24 Jan 24
8-K
ROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
8 Jan 24
8-K
Entry into a Material Definitive Agreement
27 Dec 23
8-K
Other Events
27 Dec 23
CORRESP
Correspondence with SEC
11 Dec 23
UPLOAD
Letter from SEC
27 Nov 23
Transcripts
RPRX
Earnings call transcript
2023 Q4
15 Feb 24
RPRX
Earnings call transcript
2023 Q3
8 Nov 23
RPRX
Earnings call transcript
2023 Q2
8 Aug 23
RPRX
Earnings call transcript
2023 Q1
9 May 23
RPRX
Earnings call transcript
2022 Q4
15 Feb 23
RPRX
Earnings call transcript
2022 Q3
8 Nov 22
RPRX
Earnings call transcript
2022 Q2
4 Aug 22
RPRX
Earnings call transcript
2022 Q1
5 May 22
RPRX
Earnings call transcript
2021 Q4
15 Feb 22
RPRX
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
Henry A Fernandez
2 Apr 24
4
Bonnie L Bassler
2 Apr 24
144
Notice of proposed sale of securities
28 Feb 24
4
RORY B RIGGS
22 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
GENERAL ATLANTIC, L.P.
13 Feb 24
SC 13G/A
MORGAN STANLEY
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 936.45 mm | 936.45 mm | 936.45 mm | 936.45 mm | 936.45 mm | 936.45 mm |
Cash burn (monthly) | 412.21 mm | 4.60 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.75 bn | 30.63 mm | n/a | n/a | n/a | n/a |
Cash remaining | -1.81 bn | 905.82 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | -4.4 | 197.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
74.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 309 |
Opened positions | 35 |
Closed positions | 44 |
Increased positions | 135 |
Reduced positions | 110 |
13F shares | Current |
---|---|
Total value | 7.85 tn |
Total shares | 334.51 mm |
Total puts | 185.61 k |
Total calls | 1.15 mm |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
MS Morgan Stanley | 48.13 mm | $1.31 tn |
Mario Germano Giuliani | 43.82 mm | $0.00 |
Vanguard | 39.44 mm | $1.07 tn |
FMR | 30.43 mm | $825.79 bn |
BLK Blackrock | 20.56 mm | $558.10 bn |
Baillie Gifford & Co | 18.24 mm | $495.07 bn |
Adage Capital Partners GP, L.L.C. | 9.84 mm | $267.06 bn |
Viking Global Investors | 9.46 mm | $256.86 bn |
JPM JPMorgan Chase & Co. | 8.89 mm | $241.21 bn |
STT State Street | 8.43 mm | $228.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Bassler Bonnie L | Class A Ordinary Shares | Grant | Acquire A | No | No | 30.2283 | 1,240 | 37.48 k | 47,762 |
28 Mar 24 | Henry A Fernandez | Class A Ordinary Shares | Grant | Acquire A | No | No | 30.2283 | 1,240 | 37.48 k | 41,968 |
20 Feb 24 | Riggs Rory B | Class A Ordinary Shares | Conversion | Acquire C | No | No | 0 | 300,000 | 0.00 | 320,099 |
20 Feb 24 | Riggs Rory B | LP interests in RPI US Partners 2019, LP Class A Ordinary Shares | Conversion | Dispose C | No | No | 0 | 30,000 | 0.00 | 270,000 |
4 Jan 24 | Riggs Rory B | Class A Ordinary Shares | Sell | Dispose S | No | No | 27.5476 | 35,702 | 983.50 k | 20,099 |
3 Jan 24 | Riggs Rory B | Class A Ordinary Shares | Sell | Dispose S | No | No | 27.7867 | 199,098 | 5.53 mm | 55,801 |
2 Jan 24 | Riggs Rory B | Class A Ordinary Shares | Sell | Dispose S | No | No | 28.5165 | 235,200 | 6.71 mm | 254,899 |
29 Dec 23 | Bassler Bonnie L | Class A Ordinary Shares | Grant | Acquire A | No | No | 27.711 | 1,353 | 37.49 k | 46,522 |
News
B of A Securities Maintains Buy on Royalty Pharma, Lowers Price Target to $38
12 Apr 24
Looking Into Royalty Pharma's Recent Short Interest
4 Apr 24
Royalty Pharma Q4 Sales $596.00M Miss $673.65M Estimate, Net Income Attributable To Royalty Pharma $494M Versus Loss Of $(456)M Year Ago
15 Feb 24
Earnings Scheduled For February 15, 2024
15 Feb 24
Royalty Pharma's Earnings: A Preview
14 Feb 24
Press releases
Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education
18 Apr 24
Royalty Pharma Declares Second Quarter 2024 Dividend
17 Apr 24
Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum
16 Apr 24
AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe
11 Apr 24
Canada's Strategic Move Towards AI: An Investor and Trader's Perspective
9 Apr 24